Stack

Tirzepatide

Also known as Mounjaro, Zepbound

What it is: Dual GIP/GLP-1 receptor agonist peptide drug
What it does: Improves glycemic control and supports weight loss
Status: Approved
Evidence: High. Strong human clinical trial base.
Uses: Type 2 diabetes; obesity

Caution. Can cause GI side effects and requires medical supervision.

Summary

Tirzepatide activates both GIP and GLP-1 receptors, increasing post-meal insulin secretion and reducing food intake through central appetite pathways. In large trials it produced greater weight loss and HbA1c reductions than semaglutide, with a similar GI tolerability profile. The dual-agonist design is thought to drive stronger metabolic effects without proportionally more nausea. It is approved for diabetes and obesity in many regions.

Checked Jul 15, 2026.

Keep a record of Tirzepatide in Stack

Stack logs each dose you take, tracks what is left in the vial or bottle and shows how you kept to your plan. It records what you choose and does not recommend anything. Everything stays on your phone, with no account.

Get Stack on Google Play Peptide reconstitution calculator

More peptides

RetatrutideInvestigational · moderate evidence GHK-CuExperimental · low evidence BPC-157Investigational · low evidence TB-4Experimental · low evidence TB-500Experimental · low evidence

This entry summarises published information in plain language. It is not medical advice, a dosing recommendation or a substitute for a qualified healthcare professional. Many peptides are not approved for human use, and legal status varies by country. Check anything you rely on against primary sources.